Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
grade A 5.62 -2.26% -0.13
ABUS closed down 2.26 percent on Friday, February 16, 2018, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
6 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical ABUS trend table...

Date Alert Name Type % Chg
Feb 16 Narrow Range Bar Range Contraction 0.00%
Feb 16 NR7 Range Contraction 0.00%
Feb 16 Upper Bollinger Band Walk Strength 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 16 Overbought Stochastic Strength 0.00%
Feb 15 New Uptrend Bullish -2.26%
Feb 15 Upper Bollinger Band Walk Strength -2.26%
Feb 15 Wide Bands Range Expansion -2.26%
Feb 15 Overbought Stochastic Strength -2.26%
Feb 15 Upper Bollinger Band Touch Strength -2.26%

Older signals for ABUS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Is ABUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.25
52 Week Low 2.55
Average Volume 222,849
200-Day Moving Average 4.7843
50-Day Moving Average 5.1384
20-Day Moving Average 5.3135
10-Day Moving Average 5.402
Average True Range 0.3385
ADX 26.7
+DI 21.35
-DI 8.46
Chandelier Exit (Long, 3 ATRs ) 4.9345
Chandelier Exit (Short, 3 ATRs ) 5.8655
Upper Bollinger Band 5.8266
Lower Bollinger Band 4.8004
Percent B (%b) 0.8
BandWidth 19.31307
MACD Line 0.12
MACD Signal Line 0.0529
MACD Histogram 0.0672
Fundamentals Value
Market Cap 309.25 Million
Num Shares 55 Million
EPS -5.07
Price-to-Earnings (P/E) Ratio -1.11
Price-to-Sales 164.81
Price-to-Book 1.74
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.85
Resistance 3 (R3) 5.85 5.77 5.81
Resistance 2 (R2) 5.77 5.72 5.77 5.79
Resistance 1 (R1) 5.70 5.68 5.66 5.70 5.78
Pivot Point 5.62 5.62 5.61 5.62 5.62
Support 1 (S1) 5.55 5.57 5.51 5.55 5.46
Support 2 (S2) 5.47 5.53 5.47 5.45
Support 3 (S3) 5.40 5.47 5.43
Support 4 (S4) 5.40